Friday 6 November 2026 Export VCEL’s income statement to Excel — free account

Vericel Corporation

VCEL Healthcare Biotechnology

Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.

Revenue: +26.5%
EPS: +180.0%
Free cash flow: −19.4%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

54.47 2.69 +5.20%

Follow VCEL

Alert me

Market cap: $2.7B
P/E: 77.8×
Fwd P/E: 72.9×
Dividend yield: —
F-score: 7/9
Altman Z: 8.21
Beneish M: −2.53
Dividend safety: n/a

Overview

Vericel Corporation (VCEL) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Vericel Corporation (VCEL) trades at a P/S ratio of 8.1×. Over the past ten years it has ranged from 0.8× (November 2015) to 23.6× (June 2021); the current reading is higher than 61% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VCEL/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Vericel Corporation P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VCEL/metrics/ps-ratio">Vericel Corporation (VCEL) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	6.6×	(41.97%)
FY2024	11.3×	34.54%
FY2023	8.4×	16.63%
FY2022	7.2×	(38.38%)
FY2021	11.7×	3.99%
FY2020	11.2×	72.39%
FY2019	6.5×	(15.36%)
FY2018	7.7×	150.33%
FY2017	3.1×	150.01%
FY2016	1.2×	2.79%

Period	P/S ratio	Change
Sep 2026	6.3×	(14.57%)
Jun 2026	7.4×	32.66%
Mar 2026	5.6×	(14.78%)
Dec 2025	6.6×	6.85%
43 more quarters	Free account

Against its own ten years

Low 0.8× High 23.6×

Ten-year median 7.2×

Current reading's percentile 58

Company	P/S ratio
PHVS Pharvaris N.V. compare	n/m
VERA Vera Therapeutics, Inc. compare	n/m
BHVN Biohaven Ltd. compare	2.1×
ADMA ADMA Biologics Inc compare	5.7×
AUPH Aurinia Pharmaceuticals Inc compare	6.7×
VCEL Vericel Corporation	8.1×
PVLA Palvella Therapeutics, Inc. compare	54.1×
IMNM Immunome, Inc. compare	162×
CLDX Celldex Therapeutics, Inc. compare	2,498×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Vericel Corporation (VCEL) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on VCEL

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on VCEL

Stockrow Weekly